The SIRSA, SIRveNIB, SARAH and SORAMIC Clinical Trials - ITR8

More documents

Recommendations

Info

Asia-Pacific HCC <strong>Trials</strong> Group 2011 Ulaan Baator Seoul, Bundang, Hanoi Suwon Taipei Yangon Hong Kong Manila Bangkok Davao City Penang Brunei Kuala Lumpur Melbourne Singapore Sydney Jakarta Auckl<strong>and</strong> Bali SGH – Surgery
Tumour Response Pierce Chow FRCSE PhD ID SGH 024 ID SGH 025 ID SGH 001 28 th March 2009 8 th April 2009 6 th June 2008 11th 11 J l 2009 th July 2009 26th August 2009 3rd July 2009 SGH – Surgery ASCO 2010
Page 1 and 2: The SIRSA, SIRveNIB, SARAH and SORA
Page 3 and 4: What is the Role of Selective Inter
Page 5 and 6: Outcomes: Survival by yBCLC Stage g
Page 7 and 8: Is there a role for Y90 to be combi
Page 9: E L I G I B L E P A T I E N T S AHC
Page 13 and 14: Comparative Median Survival Asian P
Page 15 and 16: Optimal management of HCC not amend
Page 17 and 18: Asia‐Pacific Sorafenib Trial Over
Page 19 and 20: Asia-Pacific Asia Pacific Hepatocel
Page 21 and 22: Rational i for f comparing i SSIRT
Page 23 and 24: Multi-center Clinical Trials of the
Page 25 and 26: SIRveNIB RCT Milan Pierce Chow FRCS
Page 27 and 28: Pierce Chow FRCSE PhD SIRT yttrium-
Page 29 and 30: SIRveNIB SARAH • N = 360 (1:1) (S
Page 31 and 32: SIRveNIB SARAH • Study schedule:
Page 33 and 34: Pierce Chow FRCSE PhD Hepatocellula
Page 35 and 36: 1⁰ endpoint SORAMIC Trial: Schema
Page 37 and 38: Outcomes of Resection for Marginal
Page 39 and 40: Pierce Chow FRCSE PhD Can Neoadjuva
Page 41: Thank You! Pierce Chow FRCSE PhD SG

The SIRSA, SIRveNIB, SARAH and SORAMIC Clinical Trials - ITR8

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?